The Lack of Predictors for Rapid Progression in Prostate Cancer Patients Receiving Sipuleucel-T

Sipuleucel-T is an immunotherapy indicated for the treatment of metastatic prostate cancer. It offers a new mechanism to treat prostate cancer without the side effects of hormone therapies and chemotherapies. In previous studies sipuleucel-T did not delay disease progression, but demonstrated an ove...

Descripción completa

Detalles Bibliográficos
Autores principales: Ng, Laura, Heck, Wendy, Lavsa, Stacey, Crowther, David, Atkinson, Brad, Xiao, Lianchun, Araujo, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3730335/
https://www.ncbi.nlm.nih.gov/pubmed/24216988
http://dx.doi.org/10.3390/cancers5020511

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3730335/
https://www.ncbi.nlm.nih.gov/pubmed/24216988
http://dx.doi.org/10.3390/cancers5020511

Ejemplares similares